Trial
NCT02087085
A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Allergan
Collaborators
—
Condition
Geographic Atrophy
Intervention
400 µg Brimonidine Implant
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-04-23